CXCL10 blockade protects mice from cyclophosphamide-induced cystitis

Table 2 Changes in the number and percentage of CD4⁺ T cell lymphocytes.

Total CD4⁺ T cell	Group	Spleen	Iliac lymph nodes	Urinary bladder
Counts	Control Ab-treated	24.2 × 10⁶ ± 3.9	11.0 × 10⁵ ± 0.9	1.49 × 10⁴ ± 0.04
	Anti-CXCL10 Ab-treated	22.0 × 10⁶ ± 3.1	16.4 × 10⁵ ± 1.7	2.32 × 10⁴ ± 0.2
	CYP- and control Ab-treated	0.6 × 10⁶ ± 0.06*	0.1 × 10⁵ ± 0.02	36.8 × 10⁴ ± 4.6*
	CYP- and anti-CXCL10 Ab-treated	5.2 × 10⁶ ± 0.6	1.1 × 10⁵ ± 0.1*	22.9 × 10⁴ ± 3.3*
Percentage	Control Ab-treated	21.6 ± 1.3	39.3 ± 4.4	4.24 ± 0.23
	Anti-CXCL10 Ab-treated	20.8 ± 3.8	30.9 ± 3.2	16.3 ± 2.1*
	CYP- and control Ab-treated	2.4 ± 1.9	3.9 ± 0.19	50.5 ± 7.1
	CYP- and anti-CXCL10 Ab-treated	56.6 ± 6.5*	63.0 ± 7.2*	34.2 ± 3.7*

Control or anti-mouse CXCL10 Abs solutions were administered beginning 2 days prior to CYP treatment and every 2 days thereafter. Five days after CYP administration, lymphocytes from the spleen, iliac lymph nodes, and urinary bladder were isolated, stained for CD3 and CD4 expression, and analyzed by flow cytometry. The studies were repeated three times, and the data presented are the mean of the number or percent change ± SEM (n = 10). Differences between experimental groups were considered significant when p < 0.01 (*).